Organon Completes Divestiture of JADA® System to Laborie
Organon & Co. (OGN)
Company Research
Source: Business Wire
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms.Indications for UseThe JADA® System is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.ContraindicationsOngoing intrauterine pregnancyUntreated uterine ruptureUnresolved uterine inversionCurrent cervical cancerKnown uterine anomalyCurrent purulent infection of vagina, cervix, or uterusFor C-sections: Cervix WarningsAvoid excessive force when inserting JADA into the uterus or trauma to uterine wall may occur, including perforation.The safety and effectiveness of the JADA System in delivery at a gestational age Signs of patient deterioration or fa
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon & Co. (NYSE:OGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Organon & Co. (NYSE:OGN) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OGN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</aMarketBeat
- Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026Business Wire
- Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg RadiopaqueBusiness Wire
- Organon (OGN) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]Yahoo! Finance
OGN
Earnings
- 11/10/25 - Beat
OGN
Sec Filings
- 1/16/26 - Form 4/A
- 11/17/25 - Form 4
- 11/17/25 - Form 4
- OGN's page on the SEC website